WHO_AWaRe

WHO AWaRe

WHO AWaRe

Add article description

The WHO AWaRe Classification is a method to categorize antibiotics into three groups in an effort to improve appropriate antibiotic use.[1][2] The classification is based, in part, on the risk of developing antibiotic resistance and their importance to medicine.[1][3] It does not reflect effectiveness or strength.[4] It is accompanied by a book that outlines which and how to use antibiotics in 34 common infections.[5]

World Health Organization Logo

The three groups are "access", meaning use can be unrestricted, "watch", meaning care should be taken, and "reserve" meaning use should be saved for cases in which other options are not possible.[3] The recommendation is that greater than 60% of antibiotics used within a country come from the "access" group.[6]

The classification was developed by the World Health Organization (WHO) and launched in 2017.[1] It is an aspect of the WHO Model List of Essential Medicines.[3] The classification as of 2021 covers 258 items.[1] Challenges in its implementation include lack of awareness, little political will, and few resources.[6]

The WHO AWaRe Classification categorized antibiotics into three groups to improve appropriate antibiotic use, based on resistance risk and medical importance. "Access" antibiotics could be used freely, "watch" antibiotics required caution, and "reserve" antibiotics were for last-resort cases. Developed by the WHO, this classification aimed to ensure proper antibiotic utilization. A recent study conducted by Abdelsalam Elshenawy et al. at an English NHS Foundation Trust examined antibiotic prescribing trends during the COVID-19 pandemic, guided by the AWaRe classification. It shed light on shifting prescription patterns, highlighting the importance of antimicrobial stewardship. There was a marked rise in the consumption of antibiotics in the Watch category, while usage of certain antibiotics remained consistently high. These findings emphasized the imperative for vigilant antimicrobial stewardship to address evolving prescribing trends and combat resistance, thereby safeguarding patient health.[7]

Classification

Access

Antibiotics in the access group have a lower risk of antibiotic resistance and are typically recommended as first- and second-line treatments of infections.[6][8] They are generally inexpensive and safe.[3] They should be readily available when needed, and are highlighted in green.[3][8] Access group antibiotics include amikacin, amoxicillin, amoxicillin/clavulanic acid, ampicillin, benzylpenicillin, cefalexin, chloramphenicol, clindamycin, doxycycline, Metronidazole and nitrofurantoin.[5] Nearly 60% can be taken by mouth.[4]

Watch

Antibiotics in the watch group are typically broad-spectrum antibiotics with a greater risk of resistance.[6] They are generally only recommended if other options are not possible.[3] They should be used carefully to save their effectiveness for those cases in which "access" antibiotics are not appropriate.[8] Costs are also generally greater, and they are highlighted in yellow.[3] Included in this category are azithromycin, Cefixime, several cephalosporins, ciprofloxacin, clarithromycin, and vancomycin.[5] About 40% are available by mouth.[4]

Reserve

The reserve group are generally last line options and used for infections not treatable by other antibiotics, i.e. multi-drug-resistant organisms.[3][8] They are highlighted in red.[3] Include in this category are ceftazidime/avibactam, colistin, polymyxin B (by mouth and by injection), and linezolid.[1][5] The intravenous formulation of fosfomycin is reserve while the by mouth formulation is watch.[1] About 10% of this group is available by mouth.[4]

An occasionally included fourth group defines antibiotics whose use is not recommended.[3]

References

  1. [1]
    "2021 AWaRe classification". www.who.int. Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  2. [2]
    "2.3.5. WHO model lists of essential medicines". WHO Expert Committee on Biological Standardization: seventy-sixth report. Geneva: World Health Organization. 2023. pp. 17–18. ISBN 978-92-4-007448-4. Archived from the original on 2023-11-19. Retrieved 2023-11-17.
  3. [3]
    The WHO AWaRe (Access, Watch, Reserve) antibiotic book. 9 December 2022. Archived from the original on 13 August 2023. Retrieved 16 August 2023.
  4. [4]
    "WHO Antibiotics Portal". aware.essentialmeds.org. Retrieved 20 November 2023.
  5. [5]
    Zanichelli V, Sharland M, Cappello B, Moja L, Getahun H, Pessoa-Silva C, Sati H, van Weezenbeek C, Balkhy H, Simão M, Gandra S, Huttner B (1 April 2023). "The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance". Bulletin of the World Health Organization. 101 (4): 290–296. doi:10.2471/BLT.22.288614. ISSN 0042-9686. PMC 10042089.
  6. [6]
    Mudenda S, Daka V, Matafwali SK (2023). "World Health Organization AWaRe framework for antibiotic stewardship: Where are we now and where do we need to go? An expert viewpoint". Antimicrobial Stewardship & Healthcare Epidemiology: ASHE. 3 (1): e84. doi:10.1017/ash.2023.164. ISSN 2732-494X. PMC 10173285. PMID 37179758.
  7. [7]
    Elshenawy A (11 December 2023). "WHO AWaRe classification for antibiotic stewardship: tackling antimicrobial resistance – a descriptive study from an English NHS Foundation Trust prior to and during the COVID-19 pandemic". Frontiers Microbiology. 14. doi:10.3389/fmicb.2023.1298858.
  8. [8]
    The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02. {{cite book}}: Cite uses deprecated parameter |authors= (help)
Share this article:

This article uses material from the Wikipedia article WHO_AWaRe, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.